Real‐world data of 12‐month adjunct sodium‐glucose co‐transporter‐2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis-Reference-Cited by-同舟云学术

Real‐world data of 12‐month adjunct sodium‐glucose co‐transporter‐2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis

Published:2021-12-23 Issue: Volume: Page:
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Seufert Jochen¹^ORCID,Lanzinger Stefanie²³^ORCID,Danne Thomas⁴^ORCID,Bramlage Peter⁵,Schmid Sebastian M.³⁶,Kopp Florian⁷,Kress Stephan⁸,Fasching Peter⁹,Schäfer Claus¹⁰,Holl Reinhard W.²³,

Affiliation:

1. Division of Endocrinology and Diabetology, Department of Medicine II Medical Center, Faculty of Medicine, University of Freiburg Freiburg Germany

2. Institute for Epidemiology and Medical Biometry ZIBMT, University of Ulm Ulm Germany

3. German Center for Diabetes Research (DZD) München‐Neuherberg Germany

4. Diabetes Center for Children and Adolescents, Kinder‐ und Jugendkrankenhaus AUF DER BULT Hannover Germany

5. Institute for Pharmacology and Preventive Medicine Cloppenburg Germany

6. Institute for Endocrinology & Diabetes University of Lübeck Lübeck Germany

7. Diabetes Center Augsburg Clinical Center Augsburg Germany

8. Medical Clinic I Diabetes Center, Vinzentius‐Hospital Landau Germany

9. Medical Division for Endocrinology, Rheumatology and Acute Geriatrics Wilhelminen Hospital Vienna Vienna Austria

10. Medical Clinic II Klinikum Neumarkt, Neumarkt i.d. OPf. Neumarkt Germany

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14620

Reference9 articles.

1. Sodium‐glucose cotransporter‐2 inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews

2. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

3. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

4. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

5. Sodium–glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study;Diabetes & Metabolism;2024-01

2. Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists;Internal Medicine Journal;2023-12-29

3. The emergence of obesity in type 1 diabetes;International Journal of Obesity;2023-12-14

4. SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations;Diabetes, Metabolic Syndrome and Obesity;2023-11

5. The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats;Diabetology & Metabolic Syndrome;2023-10-31